Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma

被引：0
|
作者：
Vogel, A. [1 ]
Merle, P. [2 ]
Granito, A. [3 ]
Ikeda, M. [4 ]
LeBerre, M. -A [5 ]
Ozgurdal, K. [6 ]
Bruix, J. [7 ]
机构：
[1] Hannover Med Sch, Zentrum Innre Med, Hannover, Germany
[2] Grp Hosp Lyon Nord, Hepatol Unit, Lyon, France
[3] Univ Bologna, S Orsola Malpighi Hosp, Bologna, Italy
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Bayer HealthCare SAS, Loos, France
[6] Bayer Consumer Care AG, Basel, Switzerland
[7] Univ Barcelona, BCLC Grp, Liver Unit, Hosp Clin,IDIBAPS,CIBEREHD, Barcelona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep103
引用
收藏
页码：223 / 223
页数：1
相关论文
共 50 条
  • [1] Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Chan, S. L.
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H. J.
    Kim, S.
    Lin, Z. Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H.
    Kim, S.
    Lin, Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 134 - 134
  • [3] Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
    Robin Kate Kelley
    Rebecca Miksad
    Irfan Cicin
    YenHsun Chen
    Heinz-Josef Klümpen
    Stefano Kim
    Zhong-Zhe Lin
    Jillian Youkstetter
    Saswati Hazra
    Suvajit Sen
    Ann-Lii Cheng
    Anthony B. El-Khoueiry
    Tim Meyer
    Ghassan K. Abou-Alfa
    [J]. British Journal of Cancer, 2022, 126 : 569 - 575
  • [4] Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
    Kelley, Robin Kate
    Miksad, Rebecca
    Cicin, Irfan
    Chen, YenHsun
    Klumpen, Heinz-Josef
    Kim, Stefano
    Lin, Zhong-Zhe
    Youkstetter, Jillian
    Hazra, Saswati
    Sen, Suvajit
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    [J]. BRITISH JOURNAL OF CANCER, 2022, 126 (04) : 569 - 575
  • [5] Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy
    Ye, Linsen
    Liang, Rongpu
    Zhang, Jiebin
    Chen, Chaojin
    Chen, Xiaolong
    Zhang, Yi
    Wang, Guoying
    Yang, Yang
    Chen, Guihua
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (16)
  • [6] Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation
    Kao, Wei-Yu
    Su, Chien-Wei
    Chiou, Yi-You
    Chiu, Nai-Chi
    Liu, Chien-An
    Fang, Kuan-Chieh
    Huo, Teh-la
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Hou, Ming-Chih
    Lin, Han-Chieh
    Wu, Jaw-Ching
    [J]. RADIOLOGY, 2017, 285 (02) : 670 - 680
  • [7] Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm
    kudo, Masatoshi
    [J]. LIVER CANCER, 2017, 6 (03) : 185 - 188
  • [8] Albumin-bilirubin grade as a predictor of survival in hepatocellular carcinoma patients with thrombocytopenia
    Man, Zhong-Ran
    Gong, Xuan-Kun
    Qu, Kang-Lin
    Pang, Qing
    Wu, Bin-Quan
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (05)
  • [9] Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
    Bruix, J.
    Merle, P.
    Granito, A.
    Huang, Y. -H.
    Bodoky, G.
    Yokosuka, O.
    Rosmorduc, O.
    Breder, V.
    Gerolami, R.
    Masi, G.
    Paul, J. Ross
    Qin, S.
    Song, T.
    Bronowicki, J. -P.
    Ollivier-Hourmand, I.
    Kudo, M.
    LeBerre, M. -A.
    Baumhauer, A.
    Meinhardt, G.
    Han, G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 140 - +
  • [10] Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)
    Koechert, K.
    Meinhardt, G.
    Bruix, J.
    Teufel, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 236 - 236
12345